

Synthesis of Novel Thioglycoside Derivatives Containing Quinazolinone

Hui Huang^a (黃輝), Jian-Fang Gao^a (高建芳), Ling-Hua Cao^{a,*} (曹玲華),

Duo-Zhi Wang^a (王多志), Jian-Bin Zhang^b (張建斌),

Shu-Bao Zhou^a (周樹寶) and Yu-Qiang Zhou^a (周玉強)

^aCollege of Chemistry and Chemical Engineering, Xinjiang University,

Urumqi Xinjiang 830046, P. R. China

^bPhysics and Chemistry Test Center of Xinjiang University, Urumqi 830046, P. R. China

A series of novel thioglycoside derivatives containing 4(3*H*)-quinazolinone was designed and synthesized from 2-chloromethyl-quinazolin-4(3*H*)-ones and 1-thioglycose. Several 2-chloromethyl-quinazolin-4(3*H*)-ones were synthesized on refluxing with 2-(chloroacetyl-amino)-benzoic acid and arylamines in acetonitrile. All of the novel compounds were characterized by IR, ¹H NMR spectra and elemental analysis. The structures of compounds **7b**, **8b** and **8c** have been determined by X-ray diffraction analysis.

Keywords: 4(3*H*)-Quinazolinone; Thioglycoside; 1-Thioglycose; X-ray diffraction.

INTRODUCTION

Thioglycosides have received considerable attention in carbohydrate chemistry and carbohydrate biology, because they are widely employed as biological inhibitors, inducers and ligands for affinity chromatography of carbohydrate-processing enzymes and proteins.^{1,2} Among glycosyl donors, thioglycosides are widely used owing to their high degree of stability in many reaction conditions.³

Quinazoline compounds are reported to have physiological and pharmacological activities and applications in the treatment of several diseases such as leprosy and mental disorders and also exhibit a wide range of activities, such as antileukemic, anticonvulsant, antitumor, antimicrobial, and anti-inflammatory activities.⁴⁻⁹ A well known methaqualone¹⁰-containing quinazoline group are sedative and hypnotic drugs and have been reported to possess anticonvulsant activity. Recently, several scientists elucidated that a quinazoline nucleus possesses variable sites at positions 2 and 3 which can be suitably modified by the introduction of some active groups to yield the quinazolinone compounds in possession of higher activity.¹¹


Thus, 2-chloromethyl-quinazolin-4(3*H*)-one was linked with 1-thioglycose generating novel thioglycosides derivatives containing quinazolinone which may possess higher biological activity. The synthetic route of these compounds is shown in Scheme I.

RESULTS AND DISCUSSION

The synthetic route of 2,3-disubstituted quinazolin-4(3*H*)-ones is summarized in Scheme I. The anthranilic acid **3** was linked with chloroacetyl chloride generating **4**, which underwent cyclization by treatment with boiling acetic anhydride to form the intermediate benzoxazin-4-one **5**. In our experiment, the benzoxazinone by treatment with arylamines **6a-6d** yielded the benzamide derivatives **7a-7d**. But the benzoxazinone reacted with *o*-toluidine (**6e**) produced the quinazolinone **8e** directly. The IR spectra of **7a-7d** showed a band at about 3300 cm⁻¹ and ¹H NMR spectra showed a peak about δ 11.10, exhibiting that a N-H band existed in **7a-7d**. Moreover a single crystal of **7b** was obtained; fortunately, furthermore, X-ray diffraction confirmed the structure of *O*-benzamidobenzanilide. Errede reported¹² *O*-benzamidobenzanilide at a fusion temperature of about 250 °C for conversion to the corresponding quinazolones; in order to avoid the various products from competing reactions, we chose the reagents Ac₂O/H₂SO₄ for our investigations, and the expected product quinazolones have been obtained successfully. The benzamide derivatives **7a-7d** were converted to quinazolinone products **8a-8d** by heating in acetic acid and concentrated sulfuric acid (9:1) at 100 °C for 3 hours. In addition, the cyclization of anthranilic acid **4** with arylamine **6a-6e** led to quinazolinone **8a-8e** in 3 equiv of PCl₃/CH₃CN at 70 °C. Some re-

* Corresponding author. E-mail: clhxj@xju.edu.cn

Scheme 1



searchers have reported that benzoxazinones refluxing with amines in toluene gave a mixture of uncyclized diamides and quinazolinones,¹³ and when benzoxazinone reacted with primary amine, there were two competitive reactions; at temperatures below 150 °C the major product was *O*-benzamidobenzanilide.¹²

The intermediates **1** and **2** are easily prepared from their corresponding glycosyl bromides, followed by reaction with **8** in the system of K₂CO₃/acetone at room temperature, and the target compounds **9**, **10** were smoothly afforded in mild conditions.

Crystals of the compounds **7b**, **8b** and **8c** suitable for single crystal X-ray analysis were obtained from slow evaporation of an ethanol solution at room temperature. The structures of all the complexes were determined by direct method procedures in SHELXS-97. The structures of **7b**, **8b** and **8c** are shown in Figs. 1~3.

In Fig. 3a, there were intramolecular hydrogen bonds and intermolecular hydrogen bonds in the compound **7b** because of having an N–H bond.

EXPERIMENTAL

Melting points were determined on a Yanaco MP-S3 micro melting point apparatus and are corrected. The IR spectra were recorded as KBr pellets on a Bruker FT-IR Equinox 55 instrument. The ¹H NMR spectra were recorded on an Inova 400 (using TMS as the internal stan-




Fig. 1a. Molecular stereo configuration for compound **8b**.




Fig. 1b. A view of the crystal packing down an axis for compound **8b**.

dard, with chemical shifts expressed in δ -units in CDCl_3 as solvent). Elemental analyses were performed on a Thermo Flash EA-1112 elemental analyzer. Analytical thin-layer chromatography (TLC) was performed on silica gel GF₂₅₄ (Qingdao, China) with ethyl acetate and light petroleum (fraction boiling in the range of 60~90 °C) and detection by UV light or iodine vapor. All reagents were commercial products of analytical grade and were used directly without processing unless otherwise specified. X-ray single-crystal diffraction was recorded on a R-Axis SPIDER X-ray diffractometer.

1. Synthesis of intermediates

1.1 Synthesis of per-*O*-acetyl-thioglycoses 1~2 according to a reported method¹⁴

1: yield: 54%, m.p. 113~114 °C, lit¹⁴ m.p. 114~115 °C.




Fig. 2a. Molecular stereo configuration for compound 8c.




Fig. 2b. A view of the crystal packing down an axis for compound 8c.

2: yield: 43%, m.p. 131~133 °C.

1.2 Compound 4 was prepared according to a reported method¹⁵

4: yield 87%, m.p. 183~185 °C, lit¹⁶ m.p. 186~188 °C.

1.3 Compound 5 was prepared according to a reported method¹⁶

5: yield 93%, m.p. 93~94 °C, lit¹⁶ m.p. 95 °C.

2. General procedure for the preparation of 2-(cholo-methyl)-3-aryl-4(3*H*)-quinazolinone

Method 1

Mixtures of the benzoxazinone 5 (5 mmol), arylamines 6a-6d (5.05 mmol) and dry benzene (30 mL) were stirred for 0.5~4 h at room temperature. Then, the mixtures were refluxed for 0.5~4 h in an apparatus equipped with a water separator. The clear solution obtained in the series was evaporated to dryness at reduced pressure. The residue was crystallized from ethanol.




Fig. 3a. Molecular stereo configuration for compound 7b.




Fig. 3b. A view of the crystal packing down an axis for compound 7b.

7a: colourless acicular crystal, yield: 54%, m.p. 187~189 °C;

7b: colourless block crystal, yield: 50%, m.p. 168~170 °C;

7c: colourless acicular crystal, yield: 43%, m.p. 212~214 °C;

7d: colourless acicular crystal, yield: 38%, m.p. 182~183 °C.

To a solution of compounds **7a~7d** in ethanol was added acetic acid and concentrated sulfuric acid (9:1), and the resultant mixture was heated at 100 °C for 15 min. The mixture was cooled to room temperature and diluted with ice water. 100 mL CHCl₃ was added. The organic layer was separated, washed with saturated aqueous NaHCO₃ solution, and evaporated under vacuum to give oily products, which crystallized on standing. The crude products **8a~8d** were recrystallized from ethanol.

Method 2

To a solution of the acetylanthranilic acid (5 mmol) in CH₃CN (15 mL) was added a solution of the aniline (5 mmol) in CH₃CN (15 mL) at room temperature to give a white suspension. 15 mmol PCl₃ was added, and the resultant mixture was heated to 70 °C for 5 h. The mixture was cooled to room temperature and diluted with ice water. 100 mL CHCl₃ was added. The organic layer was separated, washed with saturated aqueous NaHCO₃ solution, and evaporated under vacuum to give an oil, which crystallized on standing. The crude products were recrystallized from ethanol.¹⁷

8a: yield: 60%, m.p. 155~156 °C, lit¹⁸ m.p. 152~154 °C, colourless block crystal.

8b: yield: 40%, m.p. 173~175 °C, colourless block crystal. ¹H NMR (400 MHz, CDCl₃), 7.23~8.30 (m, 8H), 4.29 (s, 2H, CH₂Cl₂), 2.26 (s, 3H, CH₃). Anal. calcd for C₁₆H₁₃ClN₂O: C, 67.49; H, 4.60; N, 9.84; found C, 67.63; H, 4.57; N, 9.87.

8c: yield: 43%, m.p. 138~140 °C, colourless block crystal. ¹H NMR (400 MHz, CDCl₃), 7.10~8.30 (m, 8H), 4.29 (s, 2H, CH₂Cl₂), 3.89 (s, 3H, CH₃). Anal. calcd for C₁₆H₁₃ClN₂O₂: C, 63.90; H, 4.36; N, 9.31; found C, 64.01; H, 4.38; N, 9.34.

8d: yield: 41%, m.p. 178~180 °C, colourless crystal. ¹H NMR (400 MHz, CDCl₃), 7.12~8.30 (m, 8H), 4.32 (s, 2H, CH₂Cl₂). Anal. calcd for C₁₅H₁₀Cl₂N₂O: C, 59.04; H, 3.30; N, 9.18; found C, 59.16; H, 3.29; N, 9.22.

8e: yield: 61%, m.p. 107~108 °C, lit¹⁸ m.p. 103~105 °C, colourless acicular crystal.

3. Synthesis of thioglycosides derivatives **9a~9e** and **10a~10e**

To a well-stirred suspension of K₂CO₃ (0.2 g) in acetone (20 mL) were added sequentially 1-thio-glycose (1 mmol), quinazolinone derivatives (1 mmol) and H₂O (0.1 mL). The resultant mixture was stirred at r.t for 3~4 h, diluted with CH₂Cl₂ (20 mL), filtered, and the solution was evaporated. The expected compound was isolated by crystallization from EtOH/H₂O.

9a: syrup, yield: 75%, R_f = 0.43, ¹H NMR (400 MHz, CDCl₃): δ: 1.97, 1.99, 2.00, 2.03 (3s, 12H, 4 × COCH₃), 3.52~3.56 (m, 1H, sugar ring-H-5), 3.57 (d, *J* = 14 Hz, 1H, SCH_a), 3.68 (d×d, *J*_{6,6'} = 12.4 Hz, *J*_{6,5} = 1.2 Hz, 1H, H-6), 3.74 (d, *J* = 14 Hz, 1H, SCH_b), 3.98 (d×d, *J*_{6',6} = 12.4 Hz, *J*_{6',5} = 4.8 Hz, 1H, H-6'), 4.80~5.07 (m, 3H, sugar ring-H), 5.18 (t, *J* = 9.2 Hz, 1H, C₁-H), 7.00~7.45 (m, 5H, ArH), 7.50~8.28 (m, 4H, quinazolinon-H). Anal. calcd for C₂₉H₃₀N₂O₁₀S: C, 58.19; H, 5.05; N, 4.68; found C, 58.29; H, 5.03; N, 4.70.

9b: white solid, yield: 87%, m.p. 170~171 °C; ¹H NMR (400 MHz, CDCl₃): δ: 1.96, 1.98, 2.00, 2.02 (3s, 12H, 4 × COCH₃), 2.43 (s, 3H, CH₃), 3.51~3.58 (m, 1H, sugar ring-H-5), 3.54 (d, *J* = 14 Hz, SCH_a), 3.65 (d×d, *J*_{6,6'} = 12.4 Hz, *J*_{6,5} = 1.2 Hz, 1H, H-6), 3.75 (d, *J* = 14 Hz, 1H, SCH_b), 3.94 (d×d, *J*_{6',6} = 12.4 Hz, *J*_{6',5} = 4.8 Hz, 1H, H-6'), 4.80~5.07 (m, 3H, sugar ring-H), 5.19 (t, *J* = 9.2 Hz, 1H, C₁-H), 7.05~7.32 (m, 4H, ArH), 7.51~8.28 (m, 4H, quinazolinon-H). Anal. calcd for C₃₀H₃₂N₂O₁₀S: C, 58.81; H, 5.26; N, 4.57; found C, 58.70; H, 5.24; N, 4.59.

9c: white solid, yield: 67%, m.p. 182~183 °C; ¹H NMR (400 MHz, CDCl₃): δ: 1.98, 1.98, 1.99, 2.02 (3s, 12H, 4 × COCH₃), 3.53~3.57 (m, 1H, sugar ring-H-5), 3.58 (d, *J* = 14 Hz, 1H, SCH_a), 3.66 (d×d, *J*_{6,6'} = 12.4 Hz, *J*_{6,5} = 1.2 Hz, 1H, H-6), 3.73 (d, *J* = 14 Hz, 1H, SCH_b), 3.88 (s, 3H, OCH₃), 3.96 (d×d, *J*_{6',6} = 12.4 Hz, *J*_{6',5} = 4.8 Hz, 1H, H-6'), 4.81~5.05 (m, 3H, sugar ring-H), 5.17 (t, *J* = 9.2 Hz, 1H, C₁-H), 7.02~7.28 (m, 4H, ArH), 7.52~8.29 (m, 4H, quinazolinon-H). Anal. calcd for C₃₀H₃₂N₂O₁₁S: C, 57.32; H, 5.13; N, 4.46; found C, 57.43; H, 5.11; N, 4.68.

9d: white solid, yield: 48%, m.p. 184~186 °C; ¹H NMR (400 MHz, CDCl₃): δ: 1.97, 1.99, 2.01, 2.04 (3s, 12H, 4 × COCH₃), 3.50~3.56 (m, 1H, sugar ring-H-5), 3.57 (d, *J* = 14.0 Hz, 1H, SCH_a), 3.67 (d×d, *J*_{6,6'} = 12.4 Hz, *J*_{6,5} = 1.2 Hz, 1H, H-6), 3.74 (d, *J* = 14.0 Hz, 1H, SCH_b), 3.94 (d×d, *J*_{6',6} = 12.4 Hz, *J*_{6',5} = 4.8 Hz, 1H, H-6'), 4.80~5.07 (m, 3H, sugar ring-H), 5.16 (t, *J* = 9.2 Hz, 1H, C₁-H), 7.21~7.47 (m, 4H, ArH), 7.50~8.27 (m, 4H, quinazo-

linon-H). Anal. calcd for $C_{29}H_{29}ClN_2O_{10}S$: C, 55.02; H, 4.62; N, 4.43; found C, 55.13; H, 4.64; N, 4.45.

9e: white solid, yield: 79%, m.p. 84~86 °C; 1H NMR (400 MHz, $CDCl_3$): δ : 1.97, 1.99, 2.02, 2.04 (3s, 12H, 4 \times $COCH_3$), 2.38 (s, 3H, CH_3), 3.51~3.55 (m, 1H, sugar ring-H-5), 3.59 (d, $J = 14.0$ Hz, 1H, SCH_a), 3.67 (d, $J_{6,6'} = 12.4$ Hz, $J_{6,5} = 1.2$ Hz, 1H, H-6), 3.72 (d, $J = 14.0$ Hz, 1H, SCH_b), 3.95 (d, $J_{6',6} = 12.4$ Hz, $J_{6',5} = 4.8$ Hz, 1H, H-6'), 4.80~5.07 (m, 3H, sugar ring-H), 5.16 (t, $J = 9.2$ Hz, 1H, C_1 -H), 7.03~7.31 (m, 4H, ArH), 7.49~8.28 (m, 4H, quinazolinon-H). Anal. calcd for $C_{30}H_{32}N_2O_{10}S$: C, 58.81; H, 5.26; N, 4.57; found C, 58.70; H, 5.28; N, 4.55.

10a: white solid, yield: 60%, m.p. 194~195 °C; 1H NMR (400 MHz, $CDCl_3$): δ : 1.98, 2.01, 2.02 (3s, 9H, 3 \times $COCH_3$), 3.50~3.58 (t, 1H, sugar ring-H-5), 3.60 (d, $J = 14.0$ Hz, 1H, SCH_a), 3.74 (d, $J = 14.0$ Hz, 1H, SCH_b), 3.98 (d, 1H, sugar ring-H-5'), 4.78~4.90 (m, 3H, sugar ring-H), 5.18 (t, $J = 8.0$ Hz, 1H, C_1 -H), 7.16~7.36 (m, 5H, ArH), 7.50~8.29 (m, 4H, quinazolinon-H). Anal. calcd for $C_{26}H_{26}N_2O_8S$: C, 59.31; H, 4.98; N, 5.32; found C, 59.43; H, 5.00; N, 4.30.

10b: white solid, yield: 49%, m.p. 158~159 °C; 1H NMR (400 MHz, $CDCl_3$): δ : 2.00, 2.02, 2.03 (3s, 9H, 3 \times $COCH_3$), 2.45 (s, 3H, CH_3), 3.53~3.57 (t, 1H, sugar ring-H-5), 3.59 (d, $J = 14.0$ Hz, 1H, SCH_a), 3.73 (d, $J = 14.0$ Hz, 1H, SCH_b), 4.00 (d, 1H, sugar ring-H-5'), 4.80~4.91 (m, 3H, sugar ring-H), 5.12 (t, $J = 8.0$ Hz, 1H, C_1 -H), 7.17~7.35 (m, 4H, ArH), 7.51~8.28 (m, 4H, quinazolinon-H). Anal. calcd for $C_{27}H_{28}N_2O_8S$: C, 59.99; H, 5.22; N, 5.18; found C, 59.87; H, 5.24; N, 5.16.

10c: white solid, yield: 61%, m.p. 191~192 °C; 1H NMR (400 MHz, $CDCl_3$): δ : 2.00, 2.01, 2.04 (3s, 9H, 3 \times $COCH_3$), 3.53~3.57 (t, 1H, sugar ring-H-5), 3.60 (d, $J = 14.0$ Hz, 1H, SCH_a), 3.74 (d, $J = 14.0$ Hz, 1H, SCH_b), 3.78 (s, 3H, OCH_3), 4.01 (d, 1H, sugar ring-H-5'), 4.83~4.91 (m, 3H, sugar ring-H), 5.10 (t, $J = 8.0$ Hz, 1H, C_1 -H), 7.16~7.37 (m, 4H, ArH), 7.50~8.30 (m, 4H, quinazolinon-H). Anal. calcd for $C_{27}H_{28}N_2O_9S$: C, 58.26; H, 5.07; N, 5.03; found C, 58.14; H, 5.09; N, 5.05.

10d: white solid, yield: 57%, m.p. 149~150 °C; 1H NMR (400 MHz, $CDCl_3$): δ : 1.99, 2.01, 2.04 (3s, 9H, 3 \times $COCH_3$), 3.50~3.56 (m, 1H, sugar ring-H-5), 3.57 (d, $J = 14.0$ Hz, 1H, SCH_a), 3.74 (d, $J = 14.0$ Hz, 1H, SCH_b), 4.02 (d, 1H, sugar ring-H-5'), 4.81~5.07 (m, 3H, sugar ring-H), 5.16 (t, $J = 8.0$ Hz, 1H, C_1 -H), 7.21~7.47 (m, 4H, ArH), 7.50~8.27 (m, 4H, quinazolinon-H). Anal. calcd for $C_{26}H_{25}ClN_2O_8S$: C, 55.66; H, 4.49; N, 4.99; found C,

55.55; H, 5.01; N, 5.00.

10e: white solid, yield: 46%, m.p. 148~150 °C. 1H NMR (400 MHz, $CDCl_3$): δ : 1.97, 2.00, 2.03 (3s, 9H, 3 \times $COCH_3$), 2.44 (s, 3H, CH_3), 3.53~3.58 (m, 1H, sugar ring-H-5), 3.60 (d, $J = 14.0$ Hz, 1H, SCH_a), 3.73 (d, $J = 14.0$ Hz, 1H, SCH_b), 4.01 (d, 1H, sugar ring-H-5'), 4.75~4.90 (m, 3H, sugar ring-H), 5.14 (t, $J = 8.0$ Hz, 1H, C_1 -H), 7.14~7.36 (m, 4H, ArH), 7.49~8.30 (m, 4H, quinazolinon-H). Anal. calcd for $C_{27}H_{28}N_2O_8S$: C, 59.99; H, 5.22; N, 5.18; found C, 59.87; H, 5.20; N, 5.16.

ACKNOWLEDGEMENT

This work was supported by the National Natural Science Foundation of China (Grant No. 20462006) and Xinjiang Key Laboratory of Plant Resources & Natural Products Chemistry.

SUPPLEMENTARY DATA

Complete crystallographic data for the structural analysis of compounds **7b**, **8b** and **8c** have been deposited with the Cambridge Crystallographic Data Centre, CCDC numbers 689057, 693620, and 693621, respectively. Copies of this information may be obtained free of charge from the Director, Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB2 1EZ, UK. (telephone: +44-01223-762910, facsimile: +44-01223-336033, e-mail: deposit@ccdc.cam.ac.uk or via: www.ccdc.cam.ac.uk). Supplementary data (tables containing selected bond lengths and bond angles for compound **1**) associated with this article can be found in the online version, at <http://www.ccdc.cam.ac.uk/deposit>.

Received November 14, 2008.

REFERENCES

1. Blanc-Muesser, M.; Vigne, L.; Driguez, H.; Lehmann, J.; Steck, J.; Urbahns, K. *Carbohydr. Res.* **1992**, 224, 59-71.
2. Baer, H. H.; Santoyo-González, F. *Carbohydr. Res.* **1996**, 280(2), 315-321.
3. Boons, G.-J.; Grice, P.; Leslie, R.; Ley, S. V.; Yeung, L. L. *Tetrahedron Lett.* **1993**, 34(52), 8523-8526.
4. Cao, S.-L.; Feng, Y.-P.; Jiang, Y.-Y.; Liu, S.-Y.; Ding, G.-Y.; Li, R.-T. *Bioorg. Med. Chem. Lett.* **2005**, 15(7), 1915-1917.
5. Kumar, A.; Sharma, S.; Archana; Bajaj, K.; Sharma, S.; Panwar, H.; Singh, T.; Srivastava, V. K. *Bioorg. Med. Chem.* **2003**, 11(23), 5293-5299.
6. Raffa, D.; Daidone, G.; Maggio, B.; Cascioferro, S.; Plescia, F.; Schillaci, D. *IL Farmaco* **2004**, 59(3), 215-221.

7. Archana; Srivastava, V. K.; Kumar, A. *Eur. J. Med. Chem.* **2002**, 37(11), 873-882.
8. Aly, A. A. *J. Chin. Chem. Soc.* **2007**, 54(2), 437-446.
9. Hour, M.-J.; Yang, J.-S.; Lien, J.-C.; Kuo, S.-C.; Huang, L.-J. *J. Chin. Chem. Soc.* **2007**, 54(3), 785-790.
10. Swift, J. G.; Dickens, E. A.; Beacker, B. A. *Arch. Int. Pharmacodyn.* **1960**, 128, 112-116.
11. Raffa, D.; Edler, M. C.; Daidone, G.; Maggio, B.; Merickeh, M.; Plescia, S.; Schillaci, D.; Bai, R.; Hamel, E. *Eur. J. Med. Chem.* **2004**, 39(4), 299-304.
12. Errede, L. A.; Oien, H. T.; Yarian, D. R. *J. Org. Chem.* **1977**, 42(1), 12-18.
13. Wang, S. M.; Ryder, H.; Pretswell, I.; Depledge, P.; Milton, J.; Hancox, T. C.; Dale, I.; Dangerfield, W.; Charlton, P.; Faint, R.; Dodd, R.; Hassan, S. *Bioorg. Med. Chem. Lett.* **2002**, 12, 571-574.
14. Fulton, D. A.; Stoddart, J. F. *J. Org. Chem.* **2001**, 66(25), 8309-8319.
15. Kumar, A.; Rajput, C. S.; Bhati, S. K. *Bioorg. Med. Chem.* **2007**, 15(8), 3089-3096.
16. Fetter, J.; Czuppon, T.; Hornyák, G.; Feller, A. *Tetrahedron* **1991**, 47(45), 9393-9410.
17. Xue, S.; McKenna, J.; Shieh, W.-C.; Repic, O. *J. Org. Chem.* **2004**, 69(19), 6474-6477.
18. Tani, J.; Yamada, Y.; Oine, T.; Ochiai, T.; Ishida, R.; Inoue, I. *J. Med. Chem.* **1979**, 22(1), 95-99.